Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)
Conditions
Interventions
ALT-801
Placebo
Locations
31
United States
Altimmune CTM
Birmingham, Alabama, United States
Altimmune CTM
Mesa, Arizona, United States
Altimmune CTM
Los Angeles, California, United States
National Research Institute
Los Angeles, California, United States
Altimmune CTM
Montclair, California, United States
Altimmune CTM
Santa Barbara, California, United States
Start Date
March 31, 2022
Primary Completion Date
September 28, 2023
Completion Date
September 28, 2023
Last Updated
November 29, 2023
Lead Sponsor
Altimmune, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions